Surmodics, Inc. (SRDX) 

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Show less

Over the last 12 months, insiders at Surmodics, Inc. have bought $0 and sold $0 worth of Surmodics, Inc. stock.

On average, over the past 5 years, insiders at Surmodics, Inc. have bought $0 and sold $1.76M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,500 shares for transaction amount of $30,536 was made by KNIGHT SUSAN E (director) on 2014‑05‑08.